Premium
The risk of developing metastatic disease in colorectal cancer is related to CD105‐positive vessel count
Author(s) -
Romani Antonello A.,
Borghetti Angelo F.,
Del Rio Paolo,
Sianesi Mario,
Soliani Paolo
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20456
Subject(s) - endoglin , medicine , angiogenesis , colorectal cancer , neovascularization , pathology , oncology , metastasis , cancer , gastroenterology , cd34 , biology , genetics , stem cell
Background and Objectives Angiogenesis is a complex multistep process that involves extracellular matrix remodeling, migration and proliferation of endothelial cells, and morphogenesis of microvessels. CD105 (endoglin), a co‐receptor of the TGF‐β superfamily, was proposed as a marker of neovascularization in solid malignancies. The aim of this study was to evaluate retrospectively the effect of CD105‐assessed angiogenesis on the risk of developing metastatic disease in colorectal cancer (CRC). Methods One hundred and twenty‐five paraffin‐embedded samples were analyzed by immunohistochemical methods using a CD105 monoclonal antibody. The median follow‐up was 70.8 months. Survivals were calculated from actuarial estimates, and logistic regression predicted the risk of developing metastatic disease. Results The CD105‐vessel count was strongly correlated with the occurrence of metastatic disease. The median CD105‐positive vessels in patients with and without metastatic disease were 24.7 and 13.2 vessels/mm 2 , respectively ( P < 0.001). For each one microvessel increase in the vessels count per 400× field, there was a 1.42‐fold increase in the risk of metastatic disease ( P < 0.001). Conclusions The assessment of tumor angiogenesis with anti‐CD105 was not sufficient for its use as a surrogate end point for survival because of the amount of survival variability explained was only 8% in absence of metastatic disease. In contrast, multivariate logistic regression analysis revealed that CD105‐vessels count can identify patients at high risk of metastatic disease. J. Surg. Oncol. 2006;93:446–455. © 2006 Wiley‐Liss, Inc.